The infectious complications of atopic dermatitis.

Biomarkers Dermatitis, Atopic / complications Disease Management Disease Susceptibility Drug Development Dysbiosis Humans Infection Control Infections / diagnosis Molecular Targeted Therapy

Journal

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
ISSN: 1534-4436
Titre abrégé: Ann Allergy Asthma Immunol
Pays: United States
ID NLM: 9503580

Informations de publication

Date de publication:
01 2021
Historique:
received: 30 06 2020
revised: 31 07 2020
accepted: 04 08 2020
pubmed: 11 8 2020
medline: 2 2 2021
entrez: 11 8 2020
Statut: ppublish

Résumé

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is complicated by an increased risk for skin and systemic infections. Preventive therapy for AD is based on skin barrier improvement and anti-inflammatory treatments, whereas overt skin and systemic infections require antibiotics or antiviral treatments. This review updates the pathophysiology, diagnosis, management, controversy of antibiotic use, and potential treatments of infectious complications of AD. Published literature obtained through PubMed database searches and clinical pictures. Studies relevant to the mechanisms, diagnosis, management, and potential therapy of infectious complications of AD. Skin barrier defects, type 2 inflammation, Staphylococcusaureus colonization, and cutaneous dysbiosis are the major predisposing factors for the increased infections in AD. Although overt infections require antibiotics, the use of antibiotics in AD exacerbation remains controversial. Infectious complications are a comorbidity of AD. Although not common, systemic bacterial infections and eczema herpeticum can be life-threatening. Preventive therapy of infections in AD emphasizes skin barrier improvement and anti-inflammatory therapy. The use of antibiotics in AD exacerbation requires further studies.

Identifiants

DOI: 10.1016/j.anai.2020.08.002 PMID: 32771354 PMC: PMC7411503
pubmed: 32771354
pii: S1081-1206(20)30558-5
doi: 10.1016/j.anai.2020.08.002
pmc: PMC7411503
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Meta-Analysis Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3-12

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Ann Allergy Asthma Immunol. 2019 Mar;122(3):314-317
pubmed: 30529713
Ann Allergy Asthma Immunol. 2018 Jan;120(1):10-22.e2
pubmed: 29273118
Br J Dermatol. 2020 Jun;182(6):1331-1342
pubmed: 31677162
Sci Rep. 2018 Apr 27;8(1):6665
pubmed: 29703987
Antiviral Res. 2013 May;98(2):153-7
pubmed: 23439082
Pediatr Dermatol. 2019 May;36(3):303-310
pubmed: 30968453
J Am Acad Dermatol. 2019 Jan;80(1):89-98.e3
pubmed: 30554600
JCI Insight. 2018 Feb 22;3(4):
pubmed: 29467325
J Am Acad Dermatol. 1992 Jul;27(1):29-34
pubmed: 1619073
Ann Allergy Asthma Immunol. 2019 Mar;122(3):236-240
pubmed: 30503409
FEMS Microbiol Rev. 2020 Jan 1;44(1):123-153
pubmed: 31841134
Curr Infect Dis Rep. 2019 Mar 11;21(4):12
pubmed: 30859379
Cochrane Database Syst Rev. 2019 Oct 29;2019(10):
pubmed: 31684694
J Am Acad Dermatol. 2018 Jan;78(1):62-69.e1
pubmed: 28987493
Nat Commun. 2019 Oct 16;10(1):4703
pubmed: 31619666
Clin Infect Dis. 2011 Feb 1;52(3):285-92
pubmed: 21217178
Pediatr Dermatol. 2019 Jan;36(1):115-120
pubmed: 30303549
Am J Clin Dermatol. 2019 Jun;20(3):443-456
pubmed: 31066001
Ann Allergy Asthma Immunol. 2018 Dec;121(6):653-656.e2
pubmed: 30009880
Mil Med. 2013 Dec;178(12):e1375-8
pubmed: 24306023
Am J Med. 1988 Aug 29;85(2A):49-52
pubmed: 3044093
J Allergy Clin Immunol. 2003 Oct;112(4):667-74
pubmed: 14564342
J Am Acad Dermatol. 2016 Sep;75(3):481-493.e8
pubmed: 27543211
Ann Allergy Asthma Immunol. 2019 Mar;122(3):263-269
pubmed: 30550810
Am J Clin Dermatol. 2004;5(4):217-23
pubmed: 15301569
J Drugs Dermatol. 2011 Feb;10(2):171-6
pubmed: 21283922
Pediatr Dermatol. 2019 Jul;36(4):540-541
pubmed: 30838689
Lancet. 2020 Mar 21;395(10228):923-924
pubmed: 32087123
Clin Rev Allergy Immunol. 2016 Dec;51(3):329-337
pubmed: 27377298
Ann Fam Med. 2017 Mar;15(2):124-130
pubmed: 28289111
Br J Dermatol. 2006 Oct;155(4):680-7
pubmed: 16965415
Drugs. 2020 Apr;80(6):609-615
pubmed: 32166597
J Clin Invest. 2020 Jul 1;130(7):3750-3760
pubmed: 32271718
Lancet Infect Dis. 2014 Nov;14(11):1043
pubmed: 25444404
J Invest Dermatol. 2019 Oct;139(10):2077-2079
pubmed: 31543211
Sci Rep. 2020 Feb 17;10(1):2721
pubmed: 32066784
Allergy Asthma Immunol Res. 2019 Sep;11(5):593-603
pubmed: 31332972
Ann Allergy Asthma Immunol. 2020 Nov;125(5):517-527
pubmed: 32454094
Pediatrics. 2016 Apr;137(4):
pubmed: 26933211
Ann Allergy Asthma Immunol. 2007 Jan;98(1):51-6
pubmed: 17225720
J Invest Dermatol. 2020 Feb;140(2):415-424.e10
pubmed: 31344386
Int J Dermatol. 2018 Aug;57(8):1001-1006
pubmed: 29904968
Sci Transl Med. 2020 Feb 26;12(532):
pubmed: 32102931
JAMA Dermatol. 2019 Nov 01;155(11):1269-1276
pubmed: 31365035
J Invest Dermatol. 2020 Jan;140(1):191-202.e7
pubmed: 31252032
J Allergy Clin Immunol. 2019 May;143(5):1946-1948
pubmed: 30677478
JCI Insight. 2018 May 3;3(9):
pubmed: 29720571
Acta Derm Venereol. 2013 Sep 4;93(5):515-9
pubmed: 23571785
J Invest Dermatol. 2001 Mar;116(3):480-1
pubmed: 11231333
Clin Transl Sci. 2020 Sep;13(5):994-1003
pubmed: 32315497
Dermatitis. 2020 May/Jun;31(3):223-227
pubmed: 32091463
Ann Allergy Asthma Immunol. 2017 Nov;119(5):446-451
pubmed: 28866311
J Invest Dermatol. 1975 May;64(5):313-5
pubmed: 1141706
Clin Infect Dis. 2009 Jul 1;49(1):65-71
pubmed: 19463065
Ann Allergy Asthma Immunol. 2020 Jan;124(1):28-35
pubmed: 31622669
Sci Rep. 2019 Sep 11;9(1):13082
pubmed: 31511620
Pediatr Dermatol. 2011 Jan-Feb;28(1):46-52
pubmed: 21261703
Allergy. 2018 Nov;73(11):2205-2213
pubmed: 29672867
JAMA Pediatr. 2020 Jun 1;174(6):552-562
pubmed: 32227144
Sci Transl Med. 2019 May 1;11(490):
pubmed: 31043573
Genome Res. 2012 May;22(5):850-9
pubmed: 22310478
J Invest Dermatol. 2018 Feb;138(2):265-272
pubmed: 28927889
Dermatol Ther. 2013 Nov-Dec;26(6):445-51
pubmed: 24552407
Antibiotics (Basel). 2020 Mar 31;9(4):
pubmed: 32244277
Ann Allergy Asthma Immunol. 2018 Jan;120(1):66-72.e11
pubmed: 29273131
Pediatr Dermatol. 2019 Sep;36(5):634-639
pubmed: 31328306
J Dtsch Dermatol Ges. 2013 May;11(5):437-43
pubmed: 23551950
N Engl J Med. 2002 Oct 10;347(15):1151-60
pubmed: 12374875
J Allergy Clin Immunol. 2016 Apr;137(4):1091-1102.e7
pubmed: 26431582
J Eur Acad Dermatol Venereol. 2020 May;34(5):1074-1079
pubmed: 31733162
Br J Dermatol. 2019 May;180(5):1030-1038
pubmed: 30623408
Ann Allergy Asthma Immunol. 2017 Dec;119(6):480-488
pubmed: 29223298
Pediatr Dermatol. 2019 Nov;36(6):995-996
pubmed: 31410890
Clin Infect Dis. 2014 Jul 15;59(2):e10-52
pubmed: 24973422
J Allergy Clin Immunol. 2020 Jun;145(6):1606-1614.e4
pubmed: 32179159

Auteurs

Vivian Wang (V)

Veterans Affairs Greater Los Angeles Healthcare System, United States Department of Veteran Affairs, Los Angeles, California.

Juri Boguniewicz (J)

Section of Infectious Diseases, Department of Pediatrics, Children's Hospital Colorado, Aurora, Colorado; Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.

Mark Boguniewicz (M)

Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health, Denver, Colorado; Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.

Peck Y Ong (PY)

Division of Clinical Immunology and Allergy, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California. Electronic address: pyong@chla.usc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › The infectious complications of atopic dermatitis.
questionsmedicales.fr › Maladies du système immunitaire › Hypersensibilité › Hypersensibilité immédiate › Eczéma atopique › The infectious complications of atopic dermatitis.
questionsmedicales.fr › Administration des services de santé › Gestion des soins aux patients › Prise en charge de la maladie › The infectious complications of atopic dermatitis.
questionsmedicales.fr › Phénomènes physiologiques › Constitution physique › Prédisposition aux maladies › The infectious complications of atopic dermatitis.
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › The infectious complications of atopic dermatitis.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Dysbiose › The infectious complications of atopic dermatitis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The infectious complications of atopic dermatitis.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Contrôle des maladies transmissibles › Prévention des infections › The infectious complications of atopic dermatitis.
questionsmedicales.fr › Infection › The infectious complications of atopic dermatitis.
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Thérapie moléculaire ciblée › The infectious complications of atopic dermatitis.